Ian M.Pearson


San Francisco + 1.415.875.5791 Washington + 1.202.879.3404

Ian Pearson focuses on FDA regulatory matters, with an emphasis on medical devices, combination products, and the evolving digital health sector. Before joining Jones Day, Ian served for more than seven years in the U.S. Food and Drug Administration's Office of Chief Counsel. During that time he was responsible for providing FDA with legal advice on a wide range of regulatory matters across multiple sectors. In recent years, Ian was an FDA lead in the area of digital health and worked on numerous issues pertaining to mobile medical applications, health information technology, clinical decision support software, and genetic testing.

At FDA, Ian also worked across product areas and was a member of the device counseling, combination products, and information disclosure teams. He has significant first-hand experience navigating the complexities of the Federal Food, Drug, and Cosmetic Act (FFDCA), as well as the Administrative Procedure Act, Freedom of Information Act (FOIA), Privacy Act, and provisions of the Public Health Service Act applicable to FDA regulatory matters.

Ian recently assisted agency officials with the development and implementation of the 21st Century Cures Act, which contains provisions clarifying FDA's authority to regulate certain types of medical software. He also helped to draft industry guidance on digital health topics and real-world evidence generation, and he worked closely with FDA senior staff on a multitude of related projects, including the development of FDA's Digital Health Software Precertification (PreCert) Pilot Program.


  • Athersys completes $57.6 million public offering of Common StockJones Day represented Athersys, Inc., a clinical-stage biotechnology company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life, in connection with the $57.6 million underwritten public offering of 25,587,500 shares of Common Stock.
  • Morgan Stanley Capital Partners portfolio company acquires iMark MoldingJones Day represented Morgan Stanley Capital Partners in connection with the acquisition and related financing by portfolio company Comar Holding Company, LLC of iMark Molding, LLC ("iMark") from the original iMark founders.
  • Concord Health Partners participates in $25 million investment in Pieces TechnologiesJones Day represented Concord Health Partners LLC in connection with their investment in Pieces Technologies, a healthcare artificial intelligence and technology company that connects health systems and the community to address clinical and social determinants of health.
  • Misonix acquires Solsys Medical, LLC for $109 millionJones Day advised Misonix, Inc. in its acquisition of Solsys Medical, LLC, a privately held regenerative medical company, in an all-stock transaction valued at approximately $109 million.
  • Stedical Scientific acquires PermeaDerm, Inc.Jones Day advised Stedical Scientific in its acquisition of PermeaDerm, Inc.
  • Arsenal Capital Partners acquires HistoGeneX and Caprion BiosciencesJones Day advised Arsenal Capital Partners on major investments in HistoGeneX and Caprion Biosciences and the subsequent combination of the two businesses.
  • Shore Capital Partners portfolio company acquires MD Resource CorpJones Day represented Shore Capital Partners LLC in connection with the acquisition by portfolio company Innovia Medical of Medical Device Resource Corporation, a manufacturer and distributor of liposuction and fat transfer systems for the plastic and cosmetic surgery markets.
  • Koch Disruptive Technologies leads $150 million investment in INSIGHTECJones Day advised Koch Disruptive Technologies, a subsidiary of Koch Industries, Inc. focused on finding and funding innovative and emerging companies, as the lead investor in a $150 million Series E funding round for INSIGHTEC, a commercial stage medical device company.
  • Speaking Engagements

    • October 10, 2018
      DIA Combination Products Conference: Short Course - How the MDR will Affect Combination Products
    • September 26, 2018
      ABA Life Science Legal Summit
    • February 2018
      FDLI/CDRH In-House Training Course: Introduction to US Medical Device Law and Regulation
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.